Direct access to content


Version anglaise > Outreach > Publications

Publications

****************************************
FLAGSHIP PUBLICATIONS SINCE 2011
****************************************

Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
MAbs. 2015, 7: 630-637

Eid R, Demattei MV, Episkopou H, Augé-Gouillou C, Decottignies A, Grandin N, Charbonneau M.
Genetic inactivation of ATRX leads to a decrease in the amount of telomeric cohesin and of telomere transcription in human glioma cells.
Mol Cell Biol. 2015, 35: 2818-2830

• Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Shaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bakchoul T, Denny JC, Greinacher A, Gruel Y, Roden DM.
A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.
Thromb Haemost. 2015, 113: 772-781

Rollin J, Pouplard C, Cheng Sung H, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y.
Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2.
Blood. 2015,125 : 2397-2404

Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Xavier LL, Vittecoq O, Goupille P, Mulleman D, Paintaud G.
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
Br J Clin Pharmacol. 2015, 79 : 286-297.

Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G.
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.
Clin Pharmacokinet. 2015, 54 : 551-562

• Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D.
Towards an individualised target concentration of adalimumab in rheumatoid arthritis.
Ann Rheum Dis. 2014, 73: 1428-1429

Lajoie L, Congy-Jolivet N, Bolzec A, Gouilleux-Gruart V, Sicard E, Sung HC, Peiretti F, Moreau T, Vié H, Clémenceau B, Thibault G.
ADAM17-Mediated Shedding of FcγRIIIA on Human NK Cells: Identification of the Cleavage Site and Relationship with Activation.
J Immunol. 2014, 192: 741-751

Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, Paintaud G.
Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients.
Pharmacogenet Genomics. 2014, 24 : 26-34

Desbourdes L, Ishac N, Charbonnier T, Iltis A, Ducrocq E, Herault O, Gyan E, Domenech J.
Integrity and Cell Cycle Of Leukemic Cells Are Modified By Mesenchymal Stem Cells From Healthy Individuals and AML Patients
Blood. 2013, 122 : 21

Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G.
Rituximab-induced T-cell depletion in patients with rheumatoid arthritis: Association with clinical response.
Arthritis Rheum. 2013, 65: 2783-2790

Rollin J, Pouplard C, Leroux D, May MA, Gruel Y.
Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4-heparin complexes.
J Thromb Haemost. 2013,11 : 1609-1611

• Cholez E, Debuysscher V, Bourgeais J, Boudot C, Leprince J, Tron F, Brassart B, Regnier A, Bissac E, Pecnard E, Gouilleux F, Lassoued K, Gouilleux-Gruart V
Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells.
Leukemia 2012, 26: 2390-2397

Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, Wilhelm BT, Cellot S, Sauvageau M, Andrade-Navarro M, Hébert J, Sauvageau G.
A role for GPx3 in activity of normal and leukemia stem cells.
J Exp Med 2012, 209: 895-901

Leroux D, Canépa S, Viskov C, Mourier P, Herman F, Rollin J, Gruel Y, Pouplard C.
Binding of heparin-dependent antibodies to PF4 modified byenoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay.
J Thromb Haemost 2012, 10: 430-436

Rollin J, Pouplard C, Gratacap MP, Leroux D, May MA, Aupart M, Gouilleux-Gruart V, Payrastre B, Gruel Y.
Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.
Blood 2012, 120 : 1309-1316

Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Clin Cancer Res 2011, 17 : 6329-6337

• Dhennin-Duthille I, Nyga R, Yahiaoui S, Gouilleux-Gruart V, Regnier A, Lassoued K, Gouilleux F.
The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction.
J Biol Chem 2011, 286: 5034-5042

• Palazzoli F, Bire S, Bigot Y, Bonnin-Rouleux F.
Landscape of chromatin control element patents: positioning effects in pharmaceutical bioproduction.
Nat Biotechnol 2011, 29 : 593-597



**********************************************
SELECTION OF PUBLICATIONS ISSUED IN 2015
**********************************************

Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
MAbs. 2015, 7: 630-637

• Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, Madelaine-Chambin I, Thiebaut JB, Polivka M, Paintaud G, Culine S, Janin A.
Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer.
J Clin Oncol. 2014 Dec 29. pii: JCO.2012.44.8894. [Epub ahead of print]

• Chaigne B, Watier H.
Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?
J Allergy Clin Immunol. 2015, 136: 814-816

Croix C, Prié G, Chaulet C, Viaud-Massuard MC.
Rhodium-Catalyzed 1,4-Addition of Arylboronic Acids to 3-Benzylidene-1H-pyrrolo[2,3-b]pyridin-2(3H)-one Derivatives.
J Org Chem. 2015, 80: 3264-3269.

• Dannepond C, Maruani A, Machet L, Ternant D, Paintaud G, Samimi M.
Serum Infliximab Concentrations in Psoriatic Patients Treated with Infliximab: A Systematic Review.
Acta Derm Venereol. 2015, 95: 401-406

• Dannepond C, Ternant D, Maruani A, Machet L, Paintaud G, Samimi M.
Serum infliximab concentrations and disease activity: a descriptive study of patients with psoriasis.
Br J Dermatol. 2015 Apr 9. doi: 10.1111/bjd.13831. [Epub ahead of print]

Desvignes C, Edupuganti SR, Darrouzain F, Duveau AC, Loercher A, Paintaud G, Mulleman D.
Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration.
Bioanalysis. 2015 May;7(10):1253-60. doi: 10.4155/bio.15.30.

Edupuganti SR, Eder V, Ternant D, Courtehoux M, Tranquart F, Goupille P, Paintaud G, Mulleman D.
F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot study.
Joint Bone Spine. 2015 Mar 13. pii: S1297-319X(15)00032-9. doi: 10.1016/j.jbspin.2015.01.014. [Epub ahead of print]

Eid R, Demattei MV, Episkopou H, Augé-Gouillou C, Decottignies A, Grandin N, Charbonneau M.
Genetic inactivation of ATRX leads to a decrease in the amount of telomeric cohesin and of telomere transcription in human glioma cells.
Mol Cell Biol. 2015, 35 : 2818-2830

• Fizesan M, Boin C, Aujoulat O, Newinger G, Ghergus D, Watier H, Lustig H, Ojeda-Uribe M.
Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
J Oncol Pharm Pract. 2015 Jan 12. pii: 1078155214567164. [Epub ahead of print]

Grandin N, Charbonneau M
Mec1-Dependent Phosphorylation of the Scc3 Subunit of Cohesin during Mitosis in Budding Yeast
Advances in Bioscience and Biotechnology. 2015, 6: 153-163

• Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S.
Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance.
Sci Transl Med. 2015 Feb 18;7(275):275ra21. doi: 10.1126/scitranslmed.aaa1957.

• Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouché O, Fratte S, Gonçalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C.
Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.
Cancer Epidemiol Biomarkers Prev. 2015,24 : 603-612

• Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Shaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bakchoul T, Denny JC, Greinacher A, Gruel Y, Roden DM.
A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.
Thromb Haemost. 2015, 113: 772-781

• Morel A, Passot C, Arnoult C, Dumans A, Beaumont E, Gouilleux-Gruart V, Roingeard P, Blanchard E.
The neonatal Fc receptor (FcRn) does not modulate hepatitis C virus neutralization.
J Gen Virol. 2015, 96 : 1062-1066

Pouplard C, Gruel Y.
A rapid test (STic Expert®) for the diagnosis of heparin-induced thrombocytopenia - response to De Cooman and Devreese.
Br J Haematol. 2015 May 11. doi: 10.1111/bjh.13490. [Epub ahead of print]

Rollin J, Pouplard C, Cheng Sung H, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y.
Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2.
Blood. 2015,125: 2397-2404

Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Xavier LL, Vittecoq O, Goupille P, Mulleman D, Paintaud G.
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
Br J Clin Pharmacol. 2015, 79 : 286-297.

Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G.
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
Clin Pharmacokinet. 2015 Jun 28. [Epub ahead of print]

Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G.
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.
Clin Pharmacokinet. 2015, 54: 551-562

Ternant D, Karmiris K, Vermeire S, Desvignes C, Azzopardi N, Bejan-Angoulvant T, van Assche G, Paintaud G.
Pharmacokinetics of adalimumab in Crohn's disease.
Eur J Clin Pharmacol. 2015, 71 : 1155-1157
  • Facebook
  • twitter
  • google
  • imprimer
  • version PDF
  • Send this page

Read the news of the university
Back to institution site